Structure and Molecular Recognition Mechanism of IMP-13 Metallo-β-Lactamase

Antimicrob Agents Chemother. 2020 May 21;64(6):e00123-20. doi: 10.1128/AAC.00123-20. Print 2020 May 21.

Abstract

Multidrug resistance among Gram-negative bacteria is a major global public health threat. Metallo-β-lactamases (MBLs) target the most widely used antibiotic class, the β-lactams, including the most recent generation of carbapenems. Interspecies spread renders these enzymes a serious clinical threat, and there are no clinically available inhibitors. We present the crystal structures of IMP-13, a structurally uncharacterized MBL from the Gram-negative bacterium Pseudomonas aeruginosa found in clinical outbreaks globally, and characterize the binding using solution nuclear magnetic resonance spectroscopy and molecular dynamics simulations. The crystal structures of apo IMP-13 and IMP-13 bound to four clinically relevant carbapenem antibiotics (doripenem, ertapenem, imipenem, and meropenem) are presented. Active-site plasticity and the active-site loop, where a tryptophan residue stabilizes the antibiotic core scaffold, are essential to the substrate-binding mechanism. The conserved carbapenem scaffold plays the most significant role in IMP-13 binding, explaining the broad substrate specificity. The observed plasticity and substrate-locking mechanism provide opportunities for rational drug design of novel metallo-β-lactamase inhibitors, essential in the fight against antibiotic resistance.

Keywords: IMP-13; X-ray crystallography; antibiotic resistance; imipenemase; metallo-β-lactamase; metalloenzyme; molecular dynamics; nuclear magnetic resonance; protein dynamics; solution NMR; β-lactam antibiotic.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Carbapenems
  • beta-Lactamase Inhibitors
  • beta-Lactamases* / genetics
  • beta-Lactams

Substances

  • Anti-Bacterial Agents
  • beta-Lactamase Inhibitors
  • beta-Lactamases
  • beta-Lactams
  • Carbapenems